Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Abbott Labs' second-quarter earnings beat Wall Street's projections, as the company continues to perform well in its post-branded pharmaceuticals life. However, Abbott's medical device business couldn't keep up its more successful segments, even as the company has made progress in key areas such as drug-eluting stents, while advancing into emerging markets.Overall, device sales fell 1.6% year-over-year for the quarter.
Abbott's made a few recent acquisitions to beef up this business, and the company's stellar Xience stent remains atop the industry. Are Abbott's plans for the future enough to turn around this division's slumping sales, however? Below, Motley Fool contributor Dan Carroll tells you what you need to know about Abbott's device business, and how this segment will impact this well-diversified company -- and your portfolio -- in the future.
Abbott's diversity and international edge have made this stock one of health care's safest and most reliable picks in the past. Abbott's a key reminder that investing for the long-term is the most sure-fire way to maximize your financial future. The Motley Fool's special free report, "3 Stocks That Will Help You Retire Rich," names specific investment opportunities that could help you build long-term wealth, and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.